MedTrace Logo

A Multicenter Prospective Cohort Study on the Clinical Prognosis of Ulcerative Colitis

NCT03698812 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2018-10-17

No results posted yet for this study

Summary

Mucosal healing or histological remission is an important target for the treatment of inflammatory bowel disease. In this study, patients with mucosal healing are defined as a control group, observing their clinical outcomes for 3 years, and describing the recurrence rate. The secondary objective is to study the operative rate, glucocorticoid utilization rate, treatment escalation rate, hospitalization rate and incidence of related complications.

Conditions

  • Prospective Study
  • Ulcerative Colitis in Remission

Interventions

COMBINATION_PRODUCT

Colonoscope

take off specimen

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Xinying Wang · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-09-30
Completion
2021-09-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698812 on ClinicalTrials.gov